Insider Stock Trading History of Kulkarni Samarth


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Kulkarni Samarth since year 2005. The trader's CIK number is 1682019. At the time of this reporting, Kulkarni Samarth is the Chief Business Officer of Crispr Therapeutics Ag . (stock ticker symbol CRSP). See this page for all insider trading activities at Crispr Therapeutics Ag .


Stock purchases, sales, and option exercises reported by insider Kulkarni Samarth since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-08-28 CRSP Crispr Therapeutics Ag Sale 23,154 20.09 465,163
2017-08-30 CRSP Crispr Therapeutics Ag Sale 4,000 20.00 80,000
2017-04-26 CRSP Crispr Therapeutics Ag Sale 3,275 16.74 54,816
2017-04-27 CRSP Crispr Therapeutics Ag Sale 2,206 16.78 37,023
2017-04-26 CRSP Crispr Therapeutics Ag Option Ex 3,275 1.81 5,927
2017-04-27 CRSP Crispr Therapeutics Ag Option Ex 2,206 1.81 3,992
2017-04-21 CRSP Crispr Therapeutics Ag Option Ex 3,000 1.81 5,430
2017-04-21 CRSP Crispr Therapeutics Ag Sale 3,000 17.01 51,033
2017-04-24 CRSP Crispr Therapeutics Ag Option Ex 3,500 1.81 6,335
2017-04-25 CRSP Crispr Therapeutics Ag Option Ex 5,115 1.81 9,258
2017-04-24 CRSP Crispr Therapeutics Ag Sale 3,500 16.46 57,620
2017-04-25 CRSP Crispr Therapeutics Ag Sale 5,115 16.87 86,290
2017-04-19 CRSP Crispr Therapeutics Ag Option Ex 7,258 1.81 13,136
2017-04-20 CRSP Crispr Therapeutics Ag Option Ex 2,800 1.81 5,068
2017-04-19 CRSP Crispr Therapeutics Ag Sale 7,258 18.04 130,927
2017-04-20 CRSP Crispr Therapeutics Ag Sale 2,800 17.36 48,621

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kulkarni Samarth (Chief Business Officer of Crispr Therapeutics Ag at the time of this reporting) see the Securities and Exchange Commission (SEC) website.